Lithium (Low-Dose)
Lithium (Low-Dose)
Lithium occupies a strange place in longevity science. At high doses (900–1,800 mg/day), it's a psychiatric medication with a narrow safety window that requires regular blood monitoring. At the trace levels found naturally in drinking water — roughly 1/1,000th of the clinical dose — epidemiological evidence consistently links it to lower suicide rates, reduced dementia risk, and possibly longer lifespan. Researchers including Dr. Nassir Ghaemi (Tufts/Harvard), Dr. Michael Berk (Deakin University), and Dr. Lars Kessing (University of Copenhagen) have spent decades documenting what they call lithium's "disease-modifying" effects on the aging brain. The 2026 JAMA Psychiatry review called it the most biologically plausible neuroprotective agent we're not using. But the evidence sits in an uncomfortable gap: strong enough to be intriguing, not strong enough (yet) for public health recommendations.
Evidence Tier: 🥈 Silver — Strong epidemiological signal + mechanistic plausibility + small positive clinical trials, but no large RCT for longevity outcomes yet.
⚖️ At a Glance: Pros & Cons
⚠️ We are researchers, not doctors. Nothing on this page is medical advice. Lithium at any dose can interact with medications and affect kidney/thyroid function. Consult your doctor before taking lithium — especially if you take NSAIDs, diuretics, or ACE inhibitors.
✅ Pros
Strong epidemiological signal: Multiple independent studies across 7+ countries link higher drinking-water lithium to lower suicide, dementia, and possibly all-cause mortality rates.
Well-understood mechanism: Lithium directly inhibits GSK-3β, a master kinase implicated in tau pathology, inflammation, and cellular senescence — giving it a clear biological rationale for neuroprotection.
Increases gray matter: Human MRI studies consistently show lithium increases hippocampal and cortical gray matter volume — one of the few interventions that demonstrably grows brain tissue rather than just slowing loss.
Ultra-low cost: Lithium orotate supplements cost $5–15/month. Even prescription lithium carbonate (with monitoring) costs under $20/month.
❌ Cons
Kidney risk at clinical doses: Long-term high-dose lithium can impair kidney function in 15–25% of patients. Risk at microdose/supplement levels appears minimal but is understudied.
Thyroid suppression: Lithium can reduce thyroid hormone output. Even low-dose users should monitor TSH levels, especially with pre-existing hypothyroidism.
No definitive longevity RCT: We have epidemiological signals and small disease-specific trials. The LATTICE trial showed Bayesian probability of benefit in MCI but didn't reach traditional significance — a proper longevity outcomes trial doesn't exist.
Drug interactions: NSAIDs (ibuprofen, naproxen), diuretics (hydrochlorothiazide), and ACE inhibitors (lisinopril) all increase lithium blood levels — potentially pushing even low-dose regimens into unsafe territory.
What Is Lithium?
Lithium is the lightest metal on the periodic table — element number 3. It's not synthesized; it's mined from mineral springs and brine deposits. Unlike nearly every other supplement on this site, lithium is not a vitamin, amino acid, or plant extract. It's an elemental mineral that the human body appears to use in trace amounts for neurological function.
The critical distinction for longevity: dose. There are three completely different lithium conversations:
- Pharmacological dose (900–1,800 mg/day lithium carbonate): This is bipolar disorder treatment. Blood levels of 0.6–1.2 mmol/L. Requires regular kidney, thyroid, and serum level monitoring. The evidence for suicide prevention at this dose is among the strongest in all of psychiatry — a 2013 meta-analysis of 48 trials found lithium reduced suicide risk by 60%.
- Low-dose (150–300 mg/day lithium carbonate): Blood levels of 0.2–0.4 mmol/L. Explored for mild cognitive impairment, Alzheimer's, and mood stabilization in non-bipolar populations. The LATTICE trial used this range.
- Micro-dose / supplement / drinking-water levels (0.1–5 mg/day elemental lithium): Blood levels of 0.01–0.1 mmol/L. This is the range of natural exposure and over-the-counter lithium orotate supplements. The epidemiological longevity signal lives here.
How It Works
Lithium's longevity mechanism centers on one enzyme: glycogen synthase kinase-3 beta (GSK-3β). GSK-3β is a "master switch" kinase — it phosphorylates (adds phosphate groups to) over 100 different proteins, controlling processes from glucose metabolism to gene expression to cell survival.
When GSK-3β is overactive — which happens with aging, chronic inflammation, and oxidative stress — it drives:
- Tau hyperphosphorylation: The formation of neurofibrillary tangles, one of the two pathologies defining Alzheimer's disease
- Increased inflammation: Through NF-κB pathway activation
- Reduced neurogenesis: Fewer new neurons in the hippocampus
- Impaired autophagy: Cells can't clean out damaged proteins and mitochondria
- β-catenin degradation: Disrupting the Wnt signaling pathway essential for tissue maintenance
Lithium directly inhibits GSK-3β by competing with magnesium at the enzyme's binding site. This single action cascades into multiple longevity-relevant effects:
- BDNF upregulation: Brain-derived neurotrophic factor increases, promoting neuron survival and synaptic plasticity
- Autophagy activation: Cells clear damaged components more effectively (via inositol monophosphatase inhibition, a second lithium target)
- Telomerase activity: Several studies show lithium increases telomerase, the enzyme that maintains telomere length — though the effect size and clinical relevance remain debated
- Gray matter preservation: Lithium-treated patients show increased gray matter volume on MRI, particularly in the hippocampus and prefrontal cortex — regions that typically shrink with age
- Neuroinflammation reduction: Through microglial modulation and reduced pro-inflammatory cytokine production
Notably, a 2026 paper in Translational Psychiatry (PMID 42477313) reported that endogenous brain lithium levels are markedly reduced in mild cognitive impairment and Alzheimer's disease — suggesting lithium may function as an essential trace element for brain health, with deficiency accelerating neurodegeneration.
The Longevity Connection
🧠 Brain Aging and Dementia Prevention
This is where the evidence is strongest. The 2026 nationwide U.S. ecological study (PMID 41643982) examined associations between lithium levels in drinking water and dementia prevalence across U.S. counties. The findings were striking: counties with higher lithium concentrations showed lower dementia rates in a dose-dependent pattern. This aligns with a 2024 systematic review (PMID 39212809) that found consistent negative associations between trace lithium and dementia across multiple countries including Denmark, Japan, and Texas.
The 2026 JAMA Psychiatry narrative review (PMID 42268602) went further, arguing that lithium meets many criteria for a disease-modifying agent in dementia: it targets multiple pathologies (tau, amyloid, inflammation, mitochondrial dysfunction) rather than a single pathway — the kind of multi-target approach that may be necessary for complex age-related diseases.
🫀 Cardiovascular and Stroke Risk
A 2026 study (PMID 41775701) examined lithium exposure via drinking groundwater and stroke risk across the United States, finding a significant inverse association — higher lithium, lower stroke risk. The mechanism may involve lithium's anti-inflammatory effects on vascular endothelium and its inhibition of GSK-3β in cardiac tissue. A related 2026 paper (PMID 42017411) showed low-dose lithium protected cardiac SERCA2 calcium pumps from thermal inactivation in mice, suggesting direct cardioprotective effects.
📊 Suicide and All-Cause Mortality
The lithium-in-drinking-water literature began with suicide prevention studies — and they remain the most replicated finding. Studies in Texas (1990), Japan (2009), Austria (2011), Greece (2013), Portugal (2025, PMID 40219040), and Iran (2024, PMID 39480571) all found inverse associations between water lithium levels and suicide rates. A 2025 review (PMID 38988157) concluded the evidence was "compelling but not yet actionable" for public health recommendations.
A pre-registered Swiss study (PMID 39242041) notably found no association — an important null result reminding us these are ecological studies with inherent limitations. Individual-level exposure, confounders like socioeconomic status and health care access, and regional dietary differences could all explain some of the signal.
🏗️ Clinical Trials: The LATTICE Trial and Beyond
The LATTICE trial was a pilot randomized clinical trial of low-dose lithium (150–300 mg/day) for mild cognitive impairment. The original frequentist analysis found no statistically significant effect on six co-primary outcomes. However, a 2026 Bayesian reanalysis (PMID 42521537) re-expressed the results in probabilistic terms and found a ~75% probability of benefit across multiple endpoints — not conclusive, but directionally encouraging for a pilot study.
Multiple smaller trials have examined lithium for Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Parkinson's disease. The 2026 JAMA Psychiatry review summarizes 15+ studies showing generally positive but modest effects on cognitive decline, with stronger results in longer trials.
Key Studies
| Study | Design | Key Finding |
|---|---|---|
| US Lithium & Dementia (2026) PMID 41643982 | Nationwide ecological study, all U.S. counties | Higher drinking-water lithium associated with lower dementia prevalence — dose-dependent, significant at p < 0.01 |
| Trace Lithium & Dementia Review (2024) PMID 39212809 | Systematic review, multiple countries | Consistent negative association between water lithium levels and dementia across Denmark, Japan, Texas, and other regions |
| Lithium as Disease-Modifying Agent (2026) PMID 42268602 | Narrative review, JAMA Psychiatry | 25-year evidence synthesis: lithium targets multiple Alzheimer's pathologies; strongest case for low-dose neuroprotection to date |
| LATTICE Trial Bayesian Reanalysis (2026) PMID 42521537 | RCT reanalysis, 150-300 mg/day in MCI | ~75% probability of benefit; frequentist null likely reflects pilot sample size rather than true absence of effect |
| Lithium & Stroke Risk (2026) PMID 41775701 | Ecological, U.S. groundwater | Significant inverse association between environmental lithium exposure and stroke risk |
| Portugal Suicide & Lithium (2025) PMID 40219040 | Ecological + biomonitoring, Portugal | Higher water lithium linked to lower suicide rates; biomonitoring confirmed exposure levels |
| Brain Lithium Levels in MCI/AD (2026) PMID 42477313 | Review + experimental data, Translational Psychiatry | Endogenous brain lithium markedly reduced in MCI and Alzheimer's; lithium deficiency may accelerate neurodegeneration |
| Lithium & Suicide Meta-Analysis (2013) PMID 23511238 | Meta-analysis, 48 RCTs | Lithium reduced suicide risk by 60% (OR 0.40); effect independent of mood-stabilizing properties |
Dosing and Safety
Protocol Options
| Regimen | Daily Dose | Form | Blood Level Target | Monitoring |
|---|---|---|---|---|
| Micro-dose (supplement) | 1–5 mg elemental lithium | Lithium orotate (~4 mg elemental per 100 mg orotate) | 0.01–0.1 mmol/L | Annual TSH, creatinine (optional) |
| Low-dose | 150–300 mg lithium carbonate (28–56 mg elemental) | Lithium carbonate (prescription) | 0.2–0.4 mmol/L | TSH, creatinine, lithium level every 3–6 months |
Form Selection
Lithium orotate is the most common over-the-counter form. It delivers ~4 mg of elemental lithium per 100 mg of lithium orotate. The theoretical advantage is better brain penetration (orotate salts cross the blood-brain barrier efficiently), though this is based on animal data — human comparative studies are lacking. A typical supplement dose is 5–20 mg of lithium orotate daily, providing 0.2–0.8 mg of elemental lithium.
Lithium carbonate is the prescription form used in all clinical trials and psychiatric treatment. For low-dose protocols (150–300 mg/day), it requires a prescription in most countries. Some longevity-focused physicians (following the Peter Attia / "Medicine 3.0" model) will prescribe low-dose lithium for off-label neuroprotection.
Lithium aspartate and lithium citrate exist but are less common.
Side Effects by Dose Level
| Dose Level | Common Side Effects | Serious Risks |
|---|---|---|
| Micro-dose (1–5 mg/day) | Generally well-tolerated; occasional mild GI discomfort | Theoretical thyroid suppression (monitor TSH if concerned). Minimal data on long-term micro-dose safety. |
| Low-dose (150–300 mg/day) | Mild tremor (5–10% of users), thirst, increased urination, mild nausea at initiation | Renal impairment (5–10% with prolonged use), hypothyroidism (10–20%), drug interactions (see below) |
| Full-dose (900–1,800 mg/day) | Tremor (30%), polyuria, weight gain, cognitive dulling, acne | Renal impairment (15–25%), hypothyroidism (20–35%), lithium toxicity at levels >1.5 mmol/L (confusion, seizures, coma) |
Critical Drug Interactions
- NSAIDs (ibuprofen, naproxen, diclofenac): Reduce lithium excretion → increase blood levels by 25–50%. Avoid combining, especially with low-dose lithium.
- Thiazide diuretics (HCTZ, chlorthalidone): Significantly increase lithium reabsorption → can double blood levels.
- ACE inhibitors (lisinopril, enalapril): Reduce lithium clearance → increase levels. Monitor carefully.
- Dehydration: Even at low doses, dehydration concentrates lithium. Maintain adequate fluid intake, especially during exercise or hot weather.
❓ Common Questions About Lithium
What is lithium and how does it work for longevity?
Lithium is a naturally occurring mineral element — the lightest metal — found in trace amounts in drinking water. For longevity, it works primarily by inhibiting an enzyme called GSK-3β, which acts like a master switch controlling inflammation, brain cell maintenance, and cellular cleanup. When GSK-3β is overactive (which happens with aging), it drives the brain changes seen in Alzheimer's. Lithium calms this enzyme down, increases brain-protective proteins like BDNF, and helps cells clear out damaged components.
What does the evidence actually show?
The strongest evidence is epidemiological: multiple studies across different countries show that people living in areas with more lithium in the drinking water have lower rates of dementia, suicide, and possibly stroke. A 2026 nationwide U.S. study found this dementia-lithium link held across all American counties. Small clinical trials of low-dose lithium for mild cognitive impairment show encouraging but not definitive results — a 2026 Bayesian reanalysis of the LATTICE trial suggested roughly a 75% probability the treatment helps. We're at the "promising but needs a bigger trial" stage, which is why we rate lithium as Silver-tier evidence.
What's the right dose?
It depends on your goals and risk tolerance. For general health optimization, most people use micro-dose lithium orotate supplements providing 1–5 mg of elemental lithium daily — this mimics the natural drinking-water exposure linked to benefits in epidemiological studies. For cognitive protection in people with early memory concerns, some physicians prescribe low-dose lithium carbonate at 150–300 mg/day (providing 28–56 mg elemental lithium), which requires blood monitoring every 3–6 months. The full psychiatric dose (900–1,800 mg/day) is not relevant to longevity and carries significant kidney and thyroid risks.
What are the risks and side effects?
At micro-dose/supplement levels (1–5 mg/day), side effects are minimal — most people notice nothing. The main theoretical concern is a subtle effect on thyroid function, so monitoring TSH levels annually is reasonable. At low prescription doses (150–300 mg/day), about 5–10% of users experience mild hand tremor, increased thirst, and urination. The more serious risks at these doses include reduced kidney function (5–10% with prolonged use) and reduced thyroid hormone production (10–20%). These are generally reversible when lithium is stopped. The biggest practical risk is drug interactions — NSAIDs like ibuprofen and certain blood pressure medications can push lithium levels dangerously high.
Who should avoid lithium?
People with kidney disease, untreated thyroid disorders, or significant heart disease should avoid lithium unless specifically prescribed and monitored by a physician. Pregnant women should avoid lithium particularly during the first trimester due to a small but real risk of cardiac malformations (Ebstein's anomaly). Anyone taking NSAIDs regularly (ibuprofen, naproxen), diuretics, or ACE inhibitors should not add lithium without medical supervision — these drugs increase lithium levels. If you have bipolar disorder and already take prescription lithium, do NOT add supplemental lithium on top — you're already getting more than enough.
The Bottom Line
Lithium sits at an unusual intersection in the longevity evidence hierarchy:
- Strong mechanistic case: GSK-3β inhibition is a plausible, multi-target anti-aging mechanism. Lithium does this reliably and at low concentrations.
- Consistent epidemiological signal: The drinking-water studies are the most compelling argument. When the same pattern — more lithium, less dementia/suicide — appears independently in Texas, Denmark, Japan, Austria, Portugal, Greece, and now nationwide U.S. data, you pay attention. Ecological studies can't prove causation, but the consistency across geography, methodology, and research groups is unusual.
- Small but positive clinical trials: The LATTICE trial didn't hit traditional significance, but Bayesian reanalysis suggests this was a power problem, not a null result. Every trial of lithium for neurodegeneration has trended positive — no large trial has clearly failed.
- Safety is dose-dependent: The micro-dose supplement range used in longevity circles (~1–5 mg/day) is radically different from psychiatric dosing. Most of lithium's feared side effects — kidney damage, thyroid failure, toxicity — are dose-dependent and appear minimal at 1/1,000th of the clinical dose.
Our verdict: Lithium is the most interesting supplement that almost nobody is talking about — precisely because the word "lithium" carries psychiatric baggage. The evidence for micro-dose lithium as a neuroprotective strategy is more compelling than for many popular longevity supplements with bigger marketing budgets. That said, the absence of a definitive longevity RCT means you're making a probabilistic bet based on mechanism and epidemiology, not proven cause-and-effect. If you're comfortable with that uncertainty, the risk/reward at 1–5 mg/day looks favorable. If you want to wait for the definitive trial, check back in a decade.
Who it's for: People over 40 interested in neuroprotection who understand they're betting on mechanism + epidemiology rather than proven RCT outcomes. Particularly relevant if you have a family history of Alzheimer's or cognitive decline.
Who should skip it: Anyone on NSAIDs, diuretics, or ACE inhibitors. Anyone with kidney or thyroid issues. Pregnant women. Anyone unwilling to accept that the long-term micro-dose safety data is thinner than we'd like.
Medical Disclaimer: This information is for educational and research purposes only. It does not constitute medical advice. Lithium can interact with medications and affect organ function. Never start lithium without consulting a qualified healthcare provider, especially if you take prescription medications or have kidney, thyroid, or heart conditions. The research summarized here represents our interpretation of published scientific literature and may not reflect the consensus of regulatory bodies like the FDA.
Sources
- Associations between low-dose drinking water lithium exposure and dementia: A nationwide U.S. ecological study. Environmental Pollution. 2026. PMID: 41643982.
- Trace lithium levels in drinking water and risk of dementia: a systematic review. Int J Bipolar Disord. 2024. PMID: 39212809.
- The 25-Year Evolution of Lithium as a Disease-Modifying Agent in Dementia: A Narrative Review. JAMA Psychiatry. 2026. PMID: 42268602.
- Bayesian Reanalysis of a Pilot Randomized Clinical Trial of Low-Dose Lithium in Mild Cognitive Impairment (LATTICE Trial). Am J Geriatr Psychiatry. 2026. PMID: 42521537.
- Estimated lithium exposure in drinking groundwater and stroke risks in the United States. Int J Stroke. 2026. PMID: 41775701.
- Lithium in Drinking Water and its Potential Impact on Mental Health: A Review. Curr Med Chem. 2025. PMID: 38988157.
- Association Between Natural Lithium Exposure and Suicide Rate: An Ecological and Biomonitoring Study in Portugal. Nutrients. 2025. PMID: 40219040.
- Lithium and its effects: does dose matter? Int J Bipolar Disord. 2024. PMID: 38914810.
- Revisiting the cognitive potential of lithium in Alzheimer's disease: the role of cholinergic system and brain connectivity. Transl Psychiatry. 2026. PMID: 42477313.
- Effects of low-dose lithium supplementation on thermal inactivation of SERCA in cardiac muscle of male mice. Biosci Rep. 2026. PMID: 42017411.
- Correlation between lithium concentrations in drinking water and suicide attempt in the southeast of Iran. Environ Monit Assess. 2024. PMID: 39480571.
- Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry. 2013. PMID: 23511238.
- Lithium: current state of the art and future directions. Int J Bipolar Disord. 2024. PMID: 39609318.
- A qualitative exploration of perspectives on taking lithium supplements. Ther Adv Psychopharmacol. 2026. PMID: 42500268.